RetinAI Partners with Boehringer Ingelheim to Advance Treatments for Patients with GA Using Artificial Intelligence

RetinAI Medical has announced a new partnership with Boehringer Ingelheim, which will combine RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases with the goal of improving patient outcomes in geographic atrophy (GA).

Financial terms of the deal were not disclosed. 

RetinAI’s AI tools for identifying novel biomarkers will be tested for the analysis of Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence to identify additional, novel biomarkers and predictors of disease progression, according to an RetinAL Medical news release. This integration of digital technologies and AI may help accelerate the development of urgently needed novel treatments and enable earlier and more precise diagnosis of vision loss and blindness caused by retinal diseases.